Jamey sheds light on the meticulous process of diversifying revenue streams beyond respiratory products, emphasizing the importance of strategic investment in latent disease areas like oncology. He explains the structured stage gate process that governs decision-making, from research and clinical trials to board approvals for significant investments in phase three trials.
